Betta Pharmaceuticals

E-nitiate Biopharmaceuticals is committed to the development of innovative drugs for autoimmune diseases, through independent research and development, and strategic collaborations, to address unmet medical needs and to improve the quality of human life.

Centrymed focuses on the field of tumor treatment, and its self-developed dual-antibody platform. The company's independent intellectual property rights have solved the problems of drug drugability and toxic and side effects of antibody drugs.

Capio Biosciences is a biotech company focused on delivering high-value oncology diagnostics that can help inform patient care decisions and improve outcomes. Capio Biosciences is developing an advanced platform called CapioCyte™ for the capture of circulating tumor cells (CTCs) from whole blood. By utilizing a combination of biomimetic cell rolling and dendrimer-mediated multivalent cell capture, CapioCyte delivers significantly greater capture sensitivity than other platforms currently available. It is also able to provide enriched CTCs for post capture molecular analysis such as FISH, RNA-Seq and NGS. CapioCyte is therefore an excellent tool for today’s cancer research needs, and potentially for clinical patient management in the future.

Hangzhou DAC Biotech provides an ADC drug platform with over 50 new intelligent linkers (including site-specific conjugation); 5 types of high-activity small molecule series compounds with different mechanisms; perfect antibody discovery, engineering transformation, and production process optimization technology; complete ADC drug animal in vivo and in vitro evaluation, drug structure confirmation, analytical method development and verification, and other services.

Founded in 2006 and headquartered in West Palm Beach, Florida, Xcovery is comprised of an experienced team that is dedicated to advancing next generation targeted therapeutics as promising new treatments to improve the lives of cancer patients. Xcovery’s mission is to develop low toxicity molecular targeted oral drugs which will allow continuous therapy and will not require dosing “holidays”. Low toxicity will allow a greater “therapeutic window” and the ability to more effectively treat multiple cancers with higher potency. Low toxicity will also allow our drugs to better be used in combination therapy where other, current therapies, are too toxic to be effective. Our Team Xcovery’s CEO, Sheridan Snyder, is a veteran entrepreneur who began his biotech career in 1981 when he founded Genzyme, followed by Biotage, Upstate Biotechnology and now Xcovery and Tyrogenex. Mr. Snyder has funded Xcovery’s first 5 years of development, through his personal investment vehicle, BioCatalyst International, Inc. This is consistent with his “formula” for developing more than 14 start-ups over a 40 year period, all of which are operating successfully today. Xcovery’s Chief Scientific Officer, Dr. Chris Liang, served as Director, Medicinal Chemistry at SUGEN (acquired by Pfizer in 2003) where he developed Sutent®, an FDA approved VEGFR/PDGFR angiogenesis inhibitor for the treatment of kidney cancer and second-line gastrointestinal cancer in Gleevec-resistant patients. The result of his knowledge, extensive experience and a unique set of medicinal chemistry design tools have enabled Xcovery to create a broad portfolio of kinase inhibitors. Xcovery’s Vice President, Oncology, Dr. Jay Gibbons, brings more than 25 years of oncology research and management experience to the team with a strong emphasis on translational medicine. During his previous role as AVP, Oncology Research at Wyeth, he was instrumental in filing eight IND’s and the NDA for Torisel® (temsirolimus), currently approved for the treatment of renal cell carcinoma.